A Multicentre, Randomized Controlled Clinical Trial of Scoring Balloon Versus High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Arteriovenous Graft Stenosis
- Sponsor
- DK Medical Technology (Suzhou) Co., Ltd.
- Enrollment
- 140
- Locations
- 7
- Primary Endpoint
- Target Lesion Primary Patency (TLPP) at 6 months post-procedure
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This is a multicenter, prospective, randomized controlled clinical study. Patients with hemodialysis arteriovenous graft fistula stenosis will be recruited to explore whether the scoring balloon is superior to the high pressure balloon in treating such lesions, so as to provide a basis for optimizing the treatment of such lesions.
This study will be conducted in seven (7) clinical trial institutions, with a total of 140 subjects included. After randomization, the subjects will use either the scoring balloon dilatation catheter, developed and produced by DK Medical Technology Co., Ltd., or the peripheral balloon dilatation catheter for surgical treatment. Clinical follow-up will be carried out within 5 days, 3 months, 6 months, and 12 months after the procedure.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Hemodialysis patients aged ≥18 and ≤80 years old, (Note: Hemodialysis patients in Singapore aged ≥ 21 and ≤80 years old);
- •AVG is mature and has successfully completed at least one hemodialysis treatment;
- •The target lesion is located in the AVG return vein and the venous side anastomosis;
- •The degree of stenosis of the target lesion is ≥50% (DSA visual inspection), and one of the following clinical indicators exists at the same time: Physical examination abnormalities include: open collateral veins, ipsilateral limb edema, changes in pulse characteristics, abnormal tremors, abnormal murmurs, etc.; Dialysis abnormalities include: increased venous pressure, new puncture difficulties, aspiration of thrombi, inability to reach target dialysis blood flow, prolonged haemostasis time after needle removal for 3 consecutive times, unexplained decrease in dialysis dose Kt/V (\>0.2 units), decrease in brachial artery blood flow (brachial artery blood flow \<650ml/min or decreased by 20% compared with the previous follow-up visit), etc.
- •The target lesion is primary or restenotic, consisting of one or more series of lesions, and the reference blood vessel diameter of the target lesion is between 4.0-8.0mm, and the total length of the target lesion is ≤80mm ;
- •The patient voluntarily signs the informed consent form.
Exclusion Criteria
- •The target lesion is located in the feeding artery, arterial anastomosis, artificial blood vessel puncture site, cephalic venous arch, thoracic outlet or central vein;
- •A stent has been implanted in any part of the access or there is ipsilateral central vein stenosis or occlusion that affects the function of the access;
- •Severely calcified lesions that are not expected to be dilatable with balloons;
- •Acute thrombosis or chronic total occlusion of AVG occurred at the time of enrolment;
- •The target lesion or any part of the vascular access has received PTA treatment within the last month;
- •There are thicker branch veins in the vein opening of the end-to-side anastomosis;
- •Patients who have undergone major surgical treatment within 30 days before inclusion in the study;
- •Patients known to be allergic to or intolerant to contrast media;
- •Patients receiving glucocorticoids or immunosuppressants;
- •The patient's life expectancy is less than 1 year;
Outcomes
Primary Outcomes
Target Lesion Primary Patency (TLPP) at 6 months post-procedure
Time Frame: 6 months
TLPP is terminated by postoperative target lesion failure (TLF) (including the 5 mm range before and after the target lesion) or target lesion-related vascular access thrombosis. TLF is defined as the presence of at least one clinical indicator (defined according to the NKF-K/DOQI guidelines) caused by target lesion stenosis ( ≥50% stenosis of the target lesion assessed by contrast angiography or ultrasound), including physical examination abnormalities or dialysis abnormalities. Target lesion-related vascular access thrombosis is limited to: after the thrombus is removed during AVG thrombus treatment and before balloon dilatation, it is confirmed by ultrasound/DSA that the original target lesion has a stenosis ≥ 50%, or when the balloon is expanded with low pressure (\<6 atm) during intraluminal treatment, obvious balloon residual waisting can be seen at the target lesion; simple mural thrombus at the puncture point or other parts of the graft needs to be ruled out.
Secondary Outcomes
- Clinical Success(0-5 days post-procedure)
- Target Lesion Primary Patency (TLPP) at 12 months post-procedure(12 months)
- Technical Success(0-5 days post-procedure)
- Access Circuit Secondary Patency (ACSP) 6 and 12 months after surgery(6, 12 months post-procedure)
- Acute Lumen Gain(During the procedure)
- Access Circuit Primary Patency (ACPP) at 6 and 12 months post-procedure(6, 12 months post-procedure)